{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:52:10Z","timestamp":1778903530926,"version":"3.51.4"},"reference-count":136,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"The author(s) reported there is no funding associated with the work featured in this article"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2022,6,3]]},"DOI":"10.1080\/14712598.2022.2082869","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T08:16:33Z","timestamp":1653898593000},"page":"717-734","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Emerging treatment landscape of non-muscle invasive bladder cancer"],"prefix":"10.1080","volume":"22","author":[{"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy"},{"name":"(DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Antonarelli","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy"},{"name":"(DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy"},{"name":"(DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Aurilio","sequence":"additional","affiliation":[{"name":"Division of Urogenital and Head and Neck Tumours, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Verri","sequence":"additional","affiliation":[{"name":"Division of Urogenital and Head and Neck Tumours, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[{"name":"San Raffaele Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific InstituteUniversity Vita-Salute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy"},{"name":"(DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"San Raffaele Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific InstituteUniversity Vita-Salute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"cit0001","unstructured":"WHO - International Agency for Reasearch on Cancer. Globocan [Internet]. 2020 cited 2021 Oct 2. cited 2021 Oct 2: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/30-Bladder-fact-sheet.pdf"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.22"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12601"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.07.062"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0105-y"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28147"},{"key":"cit0009","unstructured":"Babjuk M, Burger M, Capoun O, et al. European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ) [Internet]. Eur. Urol. 2021 cited 2021 Oct 2. Available from: https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6901"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"cit0013","unstructured":"FD Highlights of prescribing information: valstar (valrubicin) [Internet]. 2016 cited 2021 Oct 2. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020892s019lbl.pdf."},{"key":"cit0014","unstructured":"FDA. Highlights of prescribing information: keytruda (pembrolizumab) [Internet]. 2020 cited 2021 Oct 2. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s066lbl.pdf."},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu223"},{"issue":"1908","key":"cit0016","volume":"282","author":"NCCN","year":"1999","journal-title":"J Am Med Assoc"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215599694"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000125486.92260.b2"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.009"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-012-0234-4"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.08.022"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13474"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14153"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.045"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.10.012"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.06.030"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09572.x"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.04.010"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"cit0035","first-page":"631","volume":"39","author":"Basile G","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.015"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.129"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.034"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2014.11.003"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30496-X"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3075"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22588"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0266-z"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02749-8"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4561"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.510"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001941"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2570-0"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3064"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.08.006"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.499"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0195-1"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2197-x"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.e15587"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.6_suppl.319"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-S3-P81"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2719"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.8"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3147"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.05.032"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw373.14"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS603"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.966900"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32806"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2267"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-00716-w"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.420"},{"key":"cit0076","first-page":"652","volume":"30","author":"Ping SY","year":"2012","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq457"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160052"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.06.043"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.049460"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.020"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"cit0083","unstructured":"Corp. U of OS& D. Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC) [Internet]. Clinicaltrials.Gov. 2019 [cited 2021 Oct 2]. 2017 Jul 31-Aug-21. Available from: https:\/\/clinicaltrials.gov\/show\/NCT03167151"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4541"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-CT047"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002149.04"},{"key":"cit0087","unstructured":"Hahn NM, O'Donnell, MA, Efstathiou, JA, et al. Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non muscle invasive blasser cancer patients (HCRN GU16-243: ADAPT-BLADDER trial). SUO - 21st Annu Meet. [Internet]. 2020;Poster #22 Available from: https:\/\/suo-abstracts.secure-platform.com\/a\/gallery\/rounds\/9\/details\/876"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(21)01121-0"},{"key":"cit0089","unstructured":"Institute for Clinical and Economic Review. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, Non-Muscle invasive bladder cancer: effectiveness and value. [Internet]. 2020 cited 2021 Oct 2. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_Bladder_Cancer_Final_Report_122220-1.pdf"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.12.011"},{"key":"cit0091","unstructured":"Codex: study of inodiftagene vixteplasmid (BC-819) in unresponsive NMIBC. ClinicalTrials.gov identifier: NCT03719300 [Internet]. ClinicalTrials.gov. 2020 cited 2021 Oct 2. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03719300?term=BC-819&draw=2&rank=1"},{"key":"cit0092","unstructured":"EG-70 in patients with BCG-Unresponsive NMIBC (LEGEND STUDY) - NCT04752722. [Internet]. ClinicalTrials.gov. 2021 cited 2021 Oct 2. Available from: 2021 Oct 2: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04752722"},{"key":"cit0093","volume-title":"urotoday.com","author":"Bivalacqua T","year":"2021"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005"},{"key":"cit0095","unstructured":"Study of CG0070 given in patients with Non-muscle invasive bladder cancer, unresponsive to Bacillus-Calmette-Guerin (BOND-003) - NCT04452591 [Internet]. ClinicalTrials.gov. 2020 cited 2021 Oct 2. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04452591"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e16016"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4022"},{"key":"cit0098","unstructured":"CAVATAK (CVA21) in Non-muscle invasive bladder cancer (VLA-012 CANON) (CANON) - NCT02316171. [Internet]. ClinicalTrials.gov. 2019; cited 2021 Oct 2. Available from. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02316171?term=CVA21&cond=non+muscle+invasive+bladder+cancer&draw=2&rank=1"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002001.14"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1189"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0671"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.510"},{"key":"cit0103","unstructured":"FDA breakthrough therapy designation for N-803 [Internet]. businneswire.com. 2019. Available from: https:\/\/www.businesswire.com\/news\/home\/20191204005300\/en\/ImmunityBio-Granted-FDA-Breakthrough-Therapy-Designation-for-N-803-IL-15-Superagonist-in-Non-Muscle-Invasive-Bladder-Cancer."},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e15509"},{"key":"cit0105","first-page":"39.e1","volume":"35","author":"Donin NM","year":"2017","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"cit0106","unstructured":"Oral Lenalidomide and Intravesical BCG for therapy of bladder cancer - full text view - clinicaltrials.gov [Internet]. ClinicalTrials.gov. 2016 cited 2021 Oct 2. 2021 Oct 2. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01373294"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e16008"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1549-4"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11218"},{"key":"cit0110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/JU.0000000000000577","volume":"203","author":"Shore N","year":"2020","journal-title":"J Urol"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002001.03"},{"key":"cit0112","unstructured":"Vicinium granted fast track designation FDA [Internet]. Sesenbio. 2018. Available from: https:\/\/sesenbio.gcs-web.com\/news-releases\/news-release-details\/sesen-bio-announces-vicinium-granted-fast-track-designation-fda"},{"key":"cit0113","unstructured":"Sesen bio announces FDA acceptance and priority review of its biologics license application for vicineumTM. [Internet]. Sesen Bio Press Release. 2021. Available from: https:\/\/www.businesswire.com\/news\/home\/20210216005637\/en\/Sesen-Bio-Announces-FDA-Acceptance-and-Priority-Review-of-its-Biologics-License-Application-for-VicineumTM"},{"key":"cit0114","unstructured":"Bio S. Sesen bio receives complete response letter from FDA for VICINEUMTM. (oportuzumab monatox-qqrs) [Internet]. 2021. Available from: https:\/\/ir.sesenbio.com\/news-releases\/news-release-details\/sesen-bio-receives-complete-response-letter-fda-vicineumtm"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001977.04"},{"key":"cit0116","volume":"201","author":"Walker CH","year":"2019","journal-title":"J Urol"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.510"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e17039"},{"key":"cit0119","volume":"201","author":"Godoy G","year":"2019","journal-title":"J Urol"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6346-1"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044"},{"key":"cit0122","unstructured":"FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer. fda.gov. 2021."},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02930-7"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33019"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.04.002"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.10.030"},{"key":"cit0127","unstructured":"US Food and Drug Administration. BCG-unresponsive non-muscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for industry. [Internet]. cited Jul 2020. 2018 Availablefrom: https:\/\/www.fda.gov\/media\/101468\/download"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0977"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6967"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S176937"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00572-9"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657483"},{"key":"cit0134","unstructured":"Clinton T, et al. Response of FGFR3 alterations in high grade non muscle invasive bladder cancer treated with intravesical BCG therapy [Internet]. SUO - 20th Annu. Meet. 2019. Available from: https:\/\/suo-abstracts.secure-platform.com\/a\/gallery\/rounds\/1\/details\/424"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.06.011"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2022.2082869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:48:59Z","timestamp":1678171739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2022.2082869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":136,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1080\/14712598.2022.2082869"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2022.2082869","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}